Resources Blog Allotypes

Allotypes

Biointron 2024-01-20 Read time: 2 mins
Allotypes.jpg
Image credit: DOI: 10.1016/j.molimm.2015.03.255

In the context of immunology, allotypes are defined as detectable variations in immunoglobulins in particular constant regions. They differ from idiotypes, which are the unique antigenic markers found on the variable domains of antigen binding receptors. Allotypes exist due to polymorphisms on the genes encoding the immunoglobulin polypeptide chain in the germ line. Therefore, polymorphic epitopes can be found on immunoglobulin constant regions on both heavy and light chains.1,2

In 1956, allotypes were first identified by ex vivo studies where certain donor sera caused agglutination of erythrocytes treated with human incomplete anti-Rh antibody.2 Now, there are known allotypes on the heavy chains of IgG1, IgG2, IgG3, and IgA2 (G1m, G2m, G3m, A2m allotypes), as well as on the kappa light chains (Km allotypes).3,4 

Allotypes may be investigated for potential in monoclonal antibody therapeutics because while pathogenic targets can be neutralized by directly binding to antibody variable domains, when they are bound to the constant domain with specialized Fc receptors, this can trigger highly potent inflammatory or anti-inflammatory responses.5

Typically, therapeutic antibodies are of the IgG1 isotype. To prevent potential immune reactions, the constant region of the gamma1 chains can be modified by replacing the G1m3 allotype with the G1m17 allotype, which is considered to have lower immunogenicity.6

At Biointron, we are dedicated to accelerating your antibody discovery, optimization, and production needs. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects. 


References

  1. Goding, J. W. (1996). Genetics of Antibodies. Monoclonal Antibodies, 101–115. https://doi.org/10.1016/B978-012287023-1/50054-7

  2. Grubb, R. (1956). Agglutination Of Erythrocytescoated With “Incomplete” Anti-Rh By Certain Rheumatoid Arthritic Sera And Some Other Sera. Acta Pathologica Microbiologica Scandinavica, 39(3), 195–197. https://doi.org/10.1111/J.1699-0463.1956.TB03392.X

  3. De Lange, G.G. (1989). Polymorphisms of human immunoglobulins: Gm, Am, Em and Km allotypes. Exp. Clin. Immunogenet. 6, 7-17. 

  4. Jefferis, R., & Lefranc, M. P. (2009). Human immunoglobulin allotypes: possible implications for immunogenicity. mAbs, 1(4), 332–338. https://doi.org/10.4161/mabs.1.4.9122

  5. Warrender, A. K., & Kelton, W. (2020). Beyond Allotypes: The Influence of Allelic Diversity in Antibody Constant Domains. Frontiers in Immunology, 11, 569371. https://doi.org/10.3389/FIMMU.2020.02016/BIBTEX

  6. Lefranc, M. P. (2015). IMGT® Immunoglobulin Repertoire Analysis and Antibody Humanization. Molecular Biology of B Cells: Second Edition, 481–514. https://doi.org/10.1016/B978-0-12-397933-9.00026-6

Subscribe to our Blog

Recent Blog

Computational antibody methods schematic. DOI: 10.1093/bib/bbz095The development of therapeutic antibodies has been significantly enhanced by advancements in computational methods and artificial intelligence (AI). These technologies have streamlined the antibody discovery process, improving the abil

May 27, 2024
Blog

Welcometo Antibody Basics by Biointron,Part 8. In this episode, we’ll talk about therapeutics targeting cancer.What is cancer immunotherapy?Cancer immunotherapy leverages the body's immune system to fight cancer more selectively and effectively than traditional methods such as chemotherapy

May 24, 2024
Blog

The generation of an immune response to a vaccine. DOI: 10.1038/s41577-020-00479-7Vaccination is one of the most effective tools in preventing infectious diseases. At its core, the success of a vaccine hinges on its ability to induce a robust and lasting antibody response against a specific pathogen

May 22, 2024
Blog

Innovation orientation and goals for transforming CAR-T cell engineering. DOI: 10.1186/s13045-020-00910-5Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary cancer treatment in which engineered CARs redirect lymphocytes, typically T cells, to recognize and destroy cells expressing a sp

May 20, 2024
Blog

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.